title: Recurrent high-grade glioma treated with bevacizumab: prognostic value of MGMT methylation, EGFR status and pretreatment MRI in determining response and survival.
abstract: Although bevacizumab represented an important advance in treatment of recurrent high-grade gliomas (HGG), responses occur in fewer than half of patients. There are no validated biomarkers for anti-angiogenic therapy that are available for routine clinical use. We assessed the prognostic values of imaging and molecular markers in this patient population. MRI scans from 191 patients with recurrent HGG obtained prior to initiating bevacizumab were reviewed for areas of enhancement, necrosis, T2/FLAIR abnormality, and ADC values. Serial MRI scans following the initiation of bevacizumab were evaluated for response and progression. Non-radiographic markers including EGFR and MGMT status were also assessed with respect to response and patient survival. 65 of 191 patients (34 %) showed complete or partial response at the time of their best response MRI and demonstrated longer progression free survival (PFS) and overall survival (OS) compared to the group without response (PFS: 6.9 vs 3.5 months, OS: 10.9 vs 6.1 months). Minimum ADC values within enhancing and non-enhancing regions were lower in responders compared to those of non-responders (1,099 vs 984 × 10(-6) mm(2)/s, p = 0.006). Smaller enhancing area was associated with longer OS (HR = 1.99, p = 0.017). The ratio of T2/FLAIR to enhancing area was prognostic of OS for only the Grade III HGG subgroup (HR = 0.14, p = 0.004). Area of enhancing tumor at baseline can stratify survival in patients with recurrent HGG treated with bevacizumab. The extent of edema relative to enhancing area may have a prognostic role specific to Grade III HGG.
authors: Harvard Medical School, 250 Longwood Avenue, Boston, MA, 02115, USA.
authors: Christina
authors: C
authors: Chen
authors: Raymond
authors: R
authors: Huang
authors: Ainsley
authors: A
authors: MacLean
authors: Alona
authors: A
authors: Muzikansky
authors: Srinivasan
authors: S
authors: Mukundan
authors: Patrick Y
authors: PY
authors: Wen
authors: Andrew D
authors: AD
authors: Norden
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000068258:Bevacizumab; D001932:Brain Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000401:mortality; D019175:DNA Methylation; D015254:DNA Modification Methylases / Q000235:genetics*; D045643:DNA Repair Enzymes / Q000235:genetics*; D004273:DNA, Neoplasm / Q000235:genetics; D018450:Disease Progression; D066246:ErbB Receptors / Q000235:genetics*; D005260:Female; D005500:Follow-Up Studies; D005910:Glioma / Q000188:drug therapy / Q000235:genetics / Q000401:mortality*; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000235:genetics / Q000401:mortality*; D016133:Polymerase Chain Reaction; D011379:Prognosis; D011401:Promoter Regions, Genetic / Q000235:genetics; D012189:Retrospective Studies; D015996:Survival Rate; D025521:Tumor Suppressor Proteins / Q000235:genetics*
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D004273:DNA, Neoplasm; D025521:Tumor Suppressor Proteins; D000068258:Bevacizumab; D015254:DNA Modification Methylases; C515491:MGMT protein, human; C512478:EGFR protein, human; D066246:ErbB Receptors; D045643:DNA Repair Enzymes
references: J Neuroimaging. 2005 Oct;15(4):341-7
references: 16254399
references: J Neurooncol. 2010 Feb;96(3):423-31
references: 19859666
references: J Neurooncol. 2010 Aug;99(1):49-56
references: 20035366
references: J Magn Reson Imaging. 1999 Jan;9(1):53-60
references: 10030650
references: Radiology. 2010 May;255(2):622-8
references: 20413772
references: Radiology. 2009 Jul;252(1):182-9
references: 19561256
references: Neuro Oncol. 2011 Jan;13(1):143-51
references: 21084434
references: PLoS One. 2012;7(1):e29945
references: 22253835
references: N Engl J Med. 2005 Mar 10;352(10):987-96
references: 15758009
references: Eur J Cancer. 2012 May;48(8):1176-84
references: 22464345
references: Cancer Res. 1999 Feb 15;59(4):793-7
references: 10029064
references: J Clin Oncol. 2009 Oct 1;27(28):4733-40
references: 19720927
references: J Neurooncol. 2009 Feb;91(3):337-51
references: 19009235
references: CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29
references: 22237781
references: Neuro Oncol. 2012 May;14(5):667-73
references: 22492961
references: J Clin Oncol. 2009 May 20;27(15):2542-52
references: 19332720
references: Radiology. 2006 Dec;241(3):839-46
references: 17032910
references: Cancer Cell. 2007 Jan;11(1):83-95
references: 17222792
references: J Clin Oncol. 1990 Jul;8(7):1277-80
references: 2358840
references: J Clin Oncol. 2009 Feb 10;27(5):740-5
references: 19114704
references: J Neurooncol. 2009 Jan;91(1):69-81
references: 18810326
references: Radiology. 2009 Jun;251(3):838-45
references: 19318585
references: AJNR Am J Neuroradiol. 2012 Oct;33(9):1763-70
references: 22538078
references: Curr Neurol Neurosci Rep. 2011 Jun;11(3):336-44
references: 21234719
references: Neurology. 2008 Mar 4;70(10):779-87
references: 18316689
references: Radiology. 2002 Jul;224(1):177-83
references: 12091680
references: J Clin Oncol. 2008 Jan 10;26(2):271-8
references: 18182667
references: J Clin Oncol. 2010 Feb 20;28(6):e91-3
references: 19933906
references: J Neurooncol. 2012 Jul;108(3):491-8
references: 22426926
references: Neurology. 2006 Apr 25;66(8):1258-60
references: 16636248
references: J Clin Oncol. 2010 Apr 10;28(11):1963-72
references: 20231676
references: J Clin Oncol. 2007 Jun 20;25(18):2601-6
references: 17577040
references: Eur J Radiol. 2005 Sep;55(3):393-400
references: 16129247
references: Radiology. 2005 Jun;235(3):985-91
references: 15833979
references: AJNR Am J Neuroradiol. 2006 Jun-Jul;27(6):1362-9
references: 16775298